← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue decreased 100.0% to $0, while Net income increased 26.5% to ($39.0M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $0Watch
- Profitability — Net income ($39.0M)Watch
- Cash generation — Free cash flow N/ANote
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 0 buys; 2 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
SPRUCE BIOSCIENCES, INC.: These statements are based on information available to us as of the date of this Annual Report, and while we believe such information provides a reasonable basis for these statements, such information may be limited or incomplete.
Leadership changes
From SPRUCE BIOSCIENCES, INC.'s own filings, the day they're filed.
- Adrian Quartel · Chief Medical Officer · appointmenteff. 2026-07-27
- Keli Walbert · Director · appointmenteff. 2025-12-11
- Tiba Aynechi · member of the board of directors · departureeff. 2025-12-11
Latest filings
- 8-K · Company announcement2026-08-12
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-07-27
- 8-K · Company announcement2026-05-26
- 10-Q · Quarterly report2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about SPRUCE BIOSCIENCES, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.